ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Translational Pharmacology
Real-world data analysis of the risk of Fournier's gangrene in patients using sodiumglucose cotransporter 2 inhibitors (SGLT2i)
Provisionally accepted
- 1Charité University Medicine Berlin, Berlin, Germany
- 2Department of Nephrology and Intensive Care, St. Joseph Hospital, Berlin, Germany
- 3Charite - Universitatsmedizin Berlin, Berlin, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The aim of the present matched cohort study was to assess if patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) show an augmented risk of Fournier's gangrene (FG) compared to subjects not using SGLT2i.Methods: Retrospective data were retrieved from the TriNetX database, whereby patients using SGLT2i and individuals not using SGLT2i were assigned to cohorts I and II, respectively.After matching for age, gender distribution, and prevalence of diabetes mellitus, human immunodeficiency virus infection, alcohol abuse, liver diseases, and use of immune suppressant, a risk analysis was carried out, and risk ratio (RR) and odds ratio (OR) were determined. The outcome was defined as diagnosis of FG.Results: Before matching, cohorts I and II accounted for 192,245 and 7,810,583 subjects.After matching, 192,245 patients (40.5% females and 59.5% males; mean age 67.512.7 years) remained per cohort. Among the cohorts I and II, 186 and 312 individuals were diagnosed with FG. The according risks of 0.1% and 0.2% were significantly different (p0.001; Log-Rank test). RR and OR were 0.539 (95% CI 0.447-0.650) and 0.539 (95% CI 0.446-0.650).Conclusion: The present study found a significantly lower risk of FG in patients using SGLT2i in comparison with subjects not using SGLT2i. Due to specific limitations that come alongside with the applied study design, this result needs to be interpreted most cautiously. As the cohorts were matched for the frequency of diabetes mellitus (68.9% of the cohorts I and II) this risk factor for FG might have been mitigated among the individuals in cohort I due to the use of SGLT2i, which may in turn explain the abovementioned finding.
Keywords: Fournier's gangrene, SGLT2 inhibitors, real-world data pharmacovigilance, Necrotizing fasciitis, Diabetes Complications, Adverse drug events
Received: 09 Jun 2025; Accepted: 31 Oct 2025.
Copyright: © 2025 Hertel, Jaoulak, Heiland, Nahles, Preissner and Preissner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Moritz Hertel, moritz.hertel2208@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.